Evidence map›Paper›PMID 39876092›Full record

ArticleHepatology (Baltimore, Md.)2025

Mitochondrial genome diversity drives heterogeneity in HCC.

Tatsuhiro Shibata, Yujin Hoshida

Abstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tatsuhiro ShibataLaboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.ORCID 0000-0002-0477-210
Yujin HoshidaDivision of Digestive and Liver Diseases, Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-9430-1426

Funding

UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeffrey M Zigman · 2022 to 2026
$7.4M
Trial of Statins for Chemoprevention in Hepatocellular CarcinomaR01CA255621 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, HOSHIDA, YUJIN · 2021 to 2025
$3.6M
Reverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5M
Epigallocatechin gallate for prevention of lethal cirrhosis complicationsR01CA282178 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Yujin Hoshida, Amit Singal · 2023 to 2026
$1.8M
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosisU01CA288375 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI CHUNG, RAYMOND T, DIEHL, ANNA MAE ELIZABETH · 2023 to 2025
$1.3M
NCI NIH HHS R01 CA233794NCI NIH HHS R01 CA255621NCI NIH HHS R01 CA282178NCI NIH HHS U01 CA288375NIDDK NIH HHS P30 DK127984
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39876092
PMCPMC12358057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.